Collegium Pharmaceutical, Inc. COLL
At closeNov 3, 2026, 4:01 PM EST
After hours · Nov 3, 4:01 PM ET
- YTD
- -48.75%
- 1 year
- -34.27%
- Market cap
- 772.54M
- Revenue (ttm)
- 796.33M
- Profit margin
- 9.41%
- EPS (ttm)
- 1.27
- Shares out
- 32.43M
- P/E ratio
- 18.68
- Forward P/E
- 4.86
- YTD return
- -48.75%
- 1-year return
- -34.27%
- Volume
- 524.87K
- Avg volume
- 823.87K
- Open
- 23.67
- Previous close
- 23.68
- Day's range
- 23.49 – 23.92
- 52-week range
- 21.43 – 50.79
- Beta
- 0.73
- Analysts
- Buy
- Price target
- 53.60 (+125.9%)
- Earnings date
- Nov 5, 2026
2Y -8.99 (-27.48%)
Key statistics
- Enterprise value
- 1.56B
- PEG ratio
- 0.00
- Price / sales
- 1.47
- Price / book
- 3.75
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 8.90%
- Free cash flow
- 56.84M
- Total cash
- 421.75M
- Total debt
- 808.06M
- Return on equity
- 27.41%
- Short % of float
- 20.15%
- 50-day average
- 34.80
- 200-day average
- 39.23
Analyst view
Consensus: buy
- Strong buy2
- Buy2
- Hold1
- Sell0
- Strong sell0
Next earnings
Nov 5, 2026
Expected Nov 5, 2026. Consensus EPS estimate 1.48.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 5, 2026 | Sep 30, 2026 | 2.09 | — | — | — |
| Aug 6, 2026 | Jun 30, 2026 | 1.72 | 1.92 | +0.20 | +11.63% |
| May 7, 2026 | Mar 31, 2026 | 1.52 | 1.76 | +0.24 | +15.79% |
| Feb 26, 2026 | Dec 31, 2025 | 2.14 | 2.04 | -0.10 | -4.67% |
| Nov 6, 2025 | Sep 30, 2025 | 1.86 | 2.25 | +0.39 | +20.97% |
| Aug 7, 2025 | Jun 30, 2025 | 1.62 | 1.68 | +0.06 | +3.70% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 20, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Mar 19, 2026 | Needham | reit | Buy | Buy |
| Feb 26, 2026 | Needham | main | Buy | Buy |
| Jan 9, 2026 | Barclays | main | Overweight | Overweight |
| Jan 9, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Jan 8, 2026 | Needham | main | Buy | Buy |
About Collegium Pharmaceutical, Inc.
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. Collegium Pharmaceutical, Inc. was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. The company was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- Employees
- 423
- Website
- collegiumpharma.com
News
Earnings Preview: Collegium Pharmaceutical (COLL) Q3 Earnings Expected to Decline 
Collegium Pharmaceutical and Boston Legacy FC Expand Their Partnership Beyond Matchday to Communities Across Massachusetts 
Collegium to Report Third Quarter 2026 Financial Results on November 5, 2026 
Collegium to Present Pediatric and Real-World Research Across ADHD Portfolio at AACAP and NEI Fall Congresses 
Collegium Pharmaceutical And Grünenthal Enter Settlement Agreement On Oct 15, 2026; Terminates Grünenthal License And Consent Agreement For Territory Effective Oct 15, 2026; Co. To Pay Grünenthal $17M In Settlement 
COLL vs. DSNKY: Which Stock Is the Better Value Option? 
Collegium Pharmaceutical: Under 3x Cash Earnings After A Narrow Guidance Cut 
Does Collegium Pharmaceutical (COLL) Have the Potential to Rally 111.39% as Wall Street Analysts Expect? 
New Strong Sell Stocks for October 7th 
Collegium Launches "Start Talking ADHD" with Practical Support to Help Families Navigate Care, School and Everyday Life
Your note
Sign in to keep a note on COLL — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BOHLIN GAREN G. | Director | Stock Award(Grant) | May 13, 2026 | 71,000 |
| DIETER DAVID | General Counsel | Sale | Mar 17, 2026 | 77,071 |
| DREYER SCOTT | Officer | Sale | Mar 2, 2026 | 71,770 |
| FREUND JOHN GORDON | Director | Sale | May 17, 2026 | 115,706 |
| KARNANI VIKRAM | Chief Executive Officer | Stock Award(Grant) | Feb 9, 2026 | 197,864 |
| KUHLMANN SHIRLEY R. | General Counsel | Sale | Mar 5, 2025 | 108,137 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| BlackRock Inc | 15.83% | 5,134,027 | 0 | Mar 30, 2026 |
| Vanguard Group Inc | 6.96% | 2,256,254 | 0 | Dec 30, 2025 |
| HHG PLC | 5.63% | 1,825,651 | 0 | Mar 30, 2026 |
| Amvescap Plc. | 4.91% | 1,591,909 | 0 | Mar 30, 2026 |
| Fuller & Thaler Asset Management Inc | 4.62% | 1,499,584 | 0 | Mar 30, 2026 |
| Renaissance Technologies Corp | 4.53% | 1,469,449 | 0 | Mar 30, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Core S&P Small-Cap ETF | 6.03% | 1,954,825 | 0 | Jun 29, 2026 |
| FullerThaler Behavioral Sm-Cp Eq R6 | 4.41% | 1,430,708 | 0 | Apr 29, 2026 |
| FullerThaler Beh Small-Cap Equity SMA | 4.41% | 1,430,708 | 0 | Dec 30, 2025 |
| FullerThaler Behavioral Small-Cap Equity | 4.41% | 1,430,708 | 0 | Mar 30, 2026 |
| Eventide Gilead N | 4.14% | 1,344,376 | 0 | Mar 30, 2026 |
| Janus Henderson Hrzn Glb SC E2 USD | 3.78% | 1,226,546 | 0 | Jun 29, 2026 |